Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage

Journal of Urology

Volumn 187, Issue 4, 2012, Pages 1498-1504

  Rick, Ferenc G ^a,b   Szalontay, Luca ^a   Schally, Andrew V ^b   Block, Norman L ^b   Nadji, Mehrdad ^b   Szepeshazi, Karoly ^a   Vidaurre, Irving ^a   Zarandi, Marta ^a,b   Kovacs, Magdolna ^a,b,c   Rekasi, Zoltan ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

gonadotropin releasing hormone; growth hormone releasing hormone; inflammation; prostate; prostatic hyperplasia

Indexed keywords

ANDROSTANOLONE; CETRORELIX; CYCLOOXYGENASE 2; FINASTERIDE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; I KAPPA B; INTERLEUKIN 1BETA; JMR 132; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DIVISION; CONTROLLED STUDY; DRUG EFFECT; GROWTH HORMONE BLOOD LEVEL; HISTOLOGY; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; TREATMENT RESPONSE;

ANIMALS; DRUG THERAPY, COMBINATION; GONADOTROPIN-RELEASING HORMONE; GROWTH HORMONE-RELEASING HORMONE; MALE; ORGAN SIZE; PROSTATIC HYPERPLASIA; RATS; RATS, WISTAR; SERMORELIN;

EID: 84858702550     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.11.081     Document Type: Article

References (30)

1. C.G. Roehrborn Benign prostatic hyperplasia: an overview Rev Urol 9 suppl. 2005 S3
2. F.G. Rick, A.V. Schally, N.L. Block Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia Proc Natl Acad Sci U S A 108 2011 3755
3. A.V. Schally, J.L. Varga, J.B. Engel Antagonists of growth-hormone- releasing hormone: an emerging new therapy for cancer Nat Clin Pract Endocrinol Metab 4 2008 33
4. J.B. Engel, A.V. Schally Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone Nat Clin Pract Endocrinol Metab 3 2007 157
5. L.K. Chopin, A.C. Herington A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines Prostate 49 2001 116
6. A. Stangelberger, A.V. Schally, M. Zarandi The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers Prostate 67 2007 1339
7. F.G. Rick, A.V. Schally, N.L. Block LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia Prostate 71 2011 736
8. F. Debruyne, A.A. Gres, D.L. Arustamov Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia Eur Urol 54 2008 170
9. F.M.J. Debruyne The efficacy and safety of ozarelix, a novel GNRH antagonist, in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) J Urol 177 2007 512
10. A. Russo, F. Castiglione, A. Salonia Effects of the gonadotropin- releasing hormone antagonist ganirelix on normal micturition and prostaglandin e(2)-induced detrusor overactivity in conscious female rats Eur Urol 59 2011 868
11. M. Zarandi, J.E. Horvath, G. Halmos Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone Proc Natl Acad Sci U S A 91 1994 12298
12. S. Bajusz, V.J. Csernus, T. Janaky New antagonists of LHRH II. Inhibition and potentiation of LHRH by closely related analogues Int J Pept Protein Res 32 1988 425
13. E. Heinrich, A.V. Schally, S. Buchholz Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138 Prostate 68 2008 1763
14. R.M. Kanashiro-Takeuchi, K. Tziomalos, L.M. Takeuchi Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction Proc Natl Acad Sci U S A 107 2010 2604
15. M. Kovacs, A.V. Schally, F. Hohla A correlation of endocrine and anticancer effects of some antagonists of GHRH Peptides 31 2010 1839
16. R.S. Hubert, I. Vivanco, E. Chen STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors Proc Natl Acad Sci U S A 96 1999 14523
17. M. Azumi, H. Kobayashi, N. Aoki Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer J Urol 183 2010 2036
18. A. Siejka, A.V. Schally, N.L. Block Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix BJU Int 106 2010 1382
19. A. Siejka, A.V. Schally, N.L. Block Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells Prostate 70 2010 1087
20. E.V. Vykhovanets, S. Shukla, G.T. MacLennan Il-1 beta-induced post-transition effect of NF-kappaB provides time-dependent wave of signals for initial phase of intrapostatic inflammation Prostate 69 2009 633
21. P.J. Barnes, M. Karin Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases N Engl J Med 336 1997 1066
22. S. Morisset, C. Patry, M. Lora Regulation of cyclooxygenase-2 expression in bovine chondrocytes in culture by interleukin 1alpha, tumor necrosis factor-alpha, glucocorticoids, and 17beta-estradiol J Rheumatol 25 1998 1146
23. W.L. Smith, D.L. DeWitt, R.M. Garavito Cyclooxygenases: structural, cellular, and molecular biology Annu Rev Biochem 69 2000 145
24. A. Kirschenbaum, A.P. Klausner, R. Lee Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate Urology 56 2000 671
25. F. Hohla, A.V. Schally, K. Szepeshazi Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel Proc Natl Acad Sci U S A 103 2006 14513
26. N. Barabutis, A.V. Schally Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line Proc Natl Acad Sci U S A 105 2008 20470
27. M. Tsujii, R.N. DuBois Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 Cell 83 1995 493
28. T.M. Nicholson, W.A. Ricke Androgens and estrogens in benign prostatic hyperplasia: past, present and future Differentiation 82 2011 184
29. J.P. Hieble Animal models for benign prostatic hyperplasia Handb Exp Pharmacol 202 2011 69
30. K. Pelton, D. Di Vizio, L. Insabato Ezetimibe reduces enlarged prostate in an animal model of benign prostatic hyperplasia J Urol 184 2010 1555